|
|
|
HRTX Description — Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on developing treatments for acute care and oncology patients. Co.'s oncology care product portfolio includes SUSTOL, which is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide combination chemotherapy regimens. Co.'s acute care product portfolio includes: ZYNRELEF, which is indicated in adults for soft tissue or periarticular instillation; and APONVIE (HTX-019), which is indicated for the prevention of postoperative nausea and vomiting in adults.
Company Name: |
Heron Therapeutics Inc |
Website: |
www.herontx.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding HRTX: |
17 |
Total Market Value Held by ETFs: |
$32,005,350 |
Total Market Capitalization: |
$459,000,000 |
% of Market Cap. Held by ETFs: |
6.97% |
|
ETF |
HRTX Weight |
HRTX Amount |
VTI |
0.00% |
$10,947,357 |
IWM |
0.01% |
$7,683,051 |
VXF |
0.01% |
$6,057,599 |
IWO |
0.02% |
$2,657,443 |
ITOT |
0.00% |
$1,219,481 |
VHT |
0.01% |
$1,078,071 |
VTWO |
0.01% |
$1,014,273 |
IWC |
0.08% |
$697,838 |
VTWG |
0.02% |
$262,616 |
IWN |
0.00% |
$139,164 |
List of all 17 ETFs holding HRTX
» |
|
|
|
|
Strong Buy (3.67 out of 4)
67th percentile
|
PARTNER NEWS:Thu, Feb 29, 5:05 PM, Zacks
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates 4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -13.24% and 100.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Mon, Feb 12, 5:27 AM, Zacks
Ocular Therapeutix (OCUL) Surges 12.9%: Is This an Indication of Further Gains? Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
|
|